Glaukos director Gilbert H. Kliman sells shares value $1.5 million

Gilbert H. Kliman, a director at Glaukos Corp (NYSE:GKOS), not too long ago bought 10,000 shares of the corporate’s widespread inventory. The corporate, with a market capitalization of $8.2 billion, has seen its inventory surge almost 87% year-to-date. The sale, which happened on December 20, 2024, was a part of a pre-arranged buying and selling plan below Rule 10b5-1, adopted in June 2024. The shares had been bought at a weighted common value of $150.28, totaling roughly $1.5 million. In response to InvestingPro, the inventory is buying and selling close to its 52-week excessive of $151.92, suggesting sturdy momentum.

In a associated transaction, Kliman additionally exercised inventory choices to accumulate 10,000 shares at a value of $32 per share. Following these transactions, Kliman holds 32,336 shares straight, together with 2,611 restricted inventory models that haven’t but vested. The transactions had been filed with the SEC on December 23, 2024. InvestingPro subscribers can entry 12 extra key insights about Glaukos Corp’s monetary well being and market efficiency by way of the great Professional Analysis Report.

In different current information, Glaukos Company has submitted a New Drug Utility to the FDA for Epioxa, a non-invasive therapy for keratoconus. If accredited, Epioxa could be the primary FDA-sanctioned, non-invasive corneal cross-linking remedy. In monetary developments, Glaukos has secured roughly $53.2 million from unwinding a portion of its capped name transactions associated to its 2.75% Convertible Senior Notes due in 2027.

Analyst companies have offered various outlooks for Glaukos. Citi upgraded Glaukos from Impartial to Purchase, anticipating a constructive inflection in gross sales of its iDose product in 2025. UBS initiated protection on Glaukos with a Purchase ranking, attributing the corporate’s projected high-20% compound annual development price to the success of iDose. Mizuho (NYSE:MFG) Securities, nonetheless, retained a Impartial ranking on Glaukos however elevated the worth goal in anticipation of a major 12 months forward for the corporate.

In associated information, Procept BioRobotics initiated a public providing of widespread inventory valued at $175 million and reported strong income development of 66% within the third quarter. Morgan Stanley (NYSE:MS) initiated protection on Procept BioRobotics with an Chubby ranking, indicating a pathway for additional upside. Truist Securities maintained a Purchase ranking on Procept BioRobotics, elevating its value goal following the corporate’s sturdy third-quarter efficiency.

This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.